Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting

2024-03-13

细胞疗法临床1期免疫疗法AACR会议

BOSTON--(BUSINESS WIRE)-- Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data from its oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held in San Diego, CA. In addition, two trial-in-progress posters for Affini-T's Phase 1 clinical-stage programs targeting KRAS G12V, the company-sponsored AFNT-211 study and the Fred Hutchinson Cancer Center Cancer Center investigator-initiated AFNT-111 study, will be presented at the same conference. Poster presentation details are as follows: Title: Non-viral engineered T cell therapy specific for the hotspot mutation p53 R175H that integrates signal 1 (TCR), signal 2 (co-stimulation) and signal 3 (cytokine) and co-opts FasL-dependent apoptosis to achieve a coordinated antitumor CD4/8 T cell response Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T Abstract Number: 7242 Presenting Author: Gary Shapiro, Ph.D., VP Biology Discovery, Affini-T Therapeutics Date/Time: Sunday, April 7, 2024, 1:30 PM - 5:00 PM Title: AFNT-212: A TRAC-knocked-in KRAS G12D-specific TCR-T cell product enhanced with CD8αβ and a chimeric cytokine receptor for treatment of solid cancers Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T Abstract Number: 5973 Presenting Author: Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics Date/Time: Sunday, April 7, 2024, 1:30 PM - 5:00 PM Title: Identifying novel patient-derived T cell receptors targeting TP53 public neoantigens Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T Abstract Number: 441 Presenting Author: Michael V. Gormally, M.D., Ph.D., Fellow, Memorial Sloan Kettering Cancer Center Date/Time: Sunday, April 7, 2024, 1:30 PM - 5:00 PM Title: AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors Session: Phase I Clinical Trials in Progress 1 Abstract Number: CT076 Presenting Author: Dirk Nagorsen, M.D., Chief Medical Officer, Affini-T Therapeutics Date/Time: Monday, April 8, 2024, 9:00 AM - 12:30 PM Title: Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal, and non-small cell lung cancers with KRAS G12V mutations Session: Phase I Clinical Trials in Progress 1 Abstract Number: CT082 Presenting Author: Aude G. Chapuis, M.D., Fred Hutchinson Cancer Center Cancer Center Date/Time: Monday, April 8, 2024, 9:00 AM - 12:30 PM About Affini-T Therapeutics Affini-T Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. For more information, visit affinittx.com and follow us on LinkedIn and X, formerly known as Twitter.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构